Why did Rainbow Childrens Medicare (RAINBOW) stock move recently?

On 8/4/2026, Rainbow Childrens Medicare moved +3.8% — The stock rose following buy recommendations issued today by Anand Rathi (target Rs 1750) and Prabhudas Lilladher (target Rs 1900). This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Rainbow Childrens Medicare (RAINBOW) overvalued or fairly valued?

MarketChacha shows Rainbow Childrens Medicare's valuation in context — a forward P/E of about 38.0, a price-to-book of about 9.3 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Rainbow Childrens Medicare's revenue?

Rainbow Childrens Medicare reported revenue of ₹1,703 Cr for FY2026, with net profit of ₹278 Cr, per official filings.

What is the share price of Rainbow Childrens Medicare (RAINBOW)?

Rainbow Childrens Medicare last traded at ₹1,504.10 (-2.2% on the day), as of 8/11/2026 — a delayed quote shown for education, not investment advice.

Rainbow Childrens Medicare

RAINBOW · NSE · Healthcare · India

Snapshot

TickerRAINBOW

ExchangeNSE

SectorHealthcare

IndustryMedical Care Facilities

CountryIndia

CEOMr. Abrarali Dalal

HeadquartersHyderabad, India

Websitewww.rainbowhospitals.in

Filings tracked0

About Rainbow Childrens Medicare

Rainbow Children's Medicare Limited operates a multi-specialty paediatric, obstetrics, and gynaecology hospital chain in India. The company offers medical and healthcare services to children and women. It also provides pediatric services under brand Rainbow Children's Hospital which include newborn and pediatric intensive care; pediatric multi-specialty services; and pediatric quaternary care, such as multi-organ transplantation. In addition, the company offers women care services under Birthright brand that comprise perinatal care services, such as routine and complex obstetric care, multi-disciplinary fetal care, perinatal genetic and fertility support, and a range of gynecology treatments, as well as operates private pediatric DNB (Diplomate of National Board) training program offering postgraduate and fellowship opportunities to train future healthcare professionals. Rainbow Children's Medicare Limited was incorporated in 1998 and is based in Hyderabad, India.

Who owns it

Promoters52.6%
Institutions36.5%
Public & other10.9%

73 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend18.0% → 16.3%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 13% · PAT 10%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹557 Cr

Next fiscal year

Rev ₹2,422 Cr · EPS 39.56

Est. earnings growth +21.0%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹1,703 Cr

Net margin

16.3%

Revenue CAGR (3y)

+13.2%

Profit CAGR (3y)

+9.7%

Net profit (FY2026)

₹278 Cr

Ask MarketChacha about RAINBOW

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 4, 2026
The stock rose following buy recommendations issued today by Anand Rathi (target Rs 1750) and Prabhudas Lilladher (target Rs 1900).
source 1 ↗source 2 ↗· confidence: high

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹1,703 Cr	₹278 Cr	16.3%
FY2025	₹1,516 Cr	₹243 Cr	16.1%
FY2024	₹1,297 Cr	₹217 Cr	16.7%
FY2023	₹1,174 Cr	₹211 Cr	18.0%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q2	₹470 Cr	₹61 Cr	12.9%
2026Q1	₹460 Cr	₹77 Cr	16.8%
2025Q4	₹445 Cr	₹73 Cr	16.3%
2025Q3	₹445 Cr	₹75 Cr	16.9%
2025Q2	₹353 Cr	₹53 Cr	15.2%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.